Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Update

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 152,000 shares, a decrease of 14.2% from the May 31st total of 177,100 shares. Based on an average trading volume of 207,800 shares, the short-interest ratio is currently 0.7 days. Currently, 3.3% of the shares of the company are short sold.

Phio Pharmaceuticals Stock Performance

Shares of PHIO stock traded down $0.02 during midday trading on Monday, hitting $0.67. 21,957 shares of the company were exchanged, compared to its average volume of 265,800. The firm has a market capitalization of $3.08 million, a P/E ratio of -0.21 and a beta of 1.45. Phio Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $3.23. The firm’s 50 day moving average price is $0.74 and its two-hundred day moving average price is $0.74.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.47) earnings per share (EPS) for the quarter. Analysts expect that Phio Pharmaceuticals will post -1.82 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Phio Pharmaceuticals in a report on Tuesday, May 14th.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.